Covid Updates:-At least a fifth of the world's population may not have access to a Covid-19 vaccine by 2022,

 Covid vaccine for the worldiy.At least a fifth of the world's population may not have access to a Covid-19 vaccine by 2022, 

At least a fifth of world population may not acces the Covid-19 Vaccine

Covid Updates:

At least a fifth of the world's population may not have access to a Covid-19 vaccine by 2022, according to a study published Wednesday. Rich countries save more than half the potential dose for next year.

With the hope of a vaccine ending the pandemic that has killed an estimated 1.6 million people, Countries including the United States, the United Kingdom, and the United Arab Emirates have already begun immunization programs in an effort to end the epidemic..

Many countries hope to increase their chances of gaining access to at least one of the dozens of vaccines under development and have already distributed several different drugs.

Rich countries - just 14 percent of the world's population - have already ordered more than half of the vaccine produced by 13 top developers the following year, according to researchers at the Johns Hopkins Bloomberg School of Public Health

There are fear concerns that poorer countries will be left behind.

Even if all pharmaceutical companies produce safe vaccines and meet their global vaccine production goals, the study fears that "by 2022, at least a fifth of the world's population will not have access to vaccines."

The study, published in the medical journal "6BMJ", found that 7.48 billion doses would be delivered by November, which is the equivalent of 3.76 billion immunizanion programs.

This is resulted from a total production capacity of a maximum of 5.96 billion courses at the end of 2021.

COMMUNICATION PURCHASE SCHEME

The study estimates that up to 40 percent of leading manufacturers' vaccination courses may be available to low- and middle-income countries, but says it depends on how much wealthier countries share what they buy.

The authors, warning that public information is incomplete, call for "more transparency and accountability" to support equitable global access.

They suggest that the consequences can go beyond health.

At various levels, trade in countries and destinations in those countries may be disrupted if effective preventive or therapeutic measures, such as the Covid-19 vaccine, are not more widely available.  "

  Many countries have joined a pool of credit mechanisms, including a coalition of the World Health Organization, Epidemic Prevention Innovations and Cell Alliance Gavie - regardless of the goal, people around the world hope to have access to 19 Covid vaccines.

The initiative hopes to have two billion Vaccine by the end of 2021.

So far, however, neither the US nor Russia have joined the program.

"DANGEROUS CRISIS"

Jason Schwartz, of the Yale School of Public Health, said US involvement in coordinating efforts was "invaluable" to ensure people around the world have access to vaccines, "which will ultimately help have the devastating effect of ending the global health crisis" .

In a BMJ editorial, Schwartz said the two-dose and extremely low temperature requirements needed to store some vaccines added to the challenge for many countries.

"The operational challenges of the global Covid-19 vaccination program will be as difficult as the scientific challenges associated with the rapid development of a safe and effective vaccine," he said.

Jason Schwartz of the Yale School of Public Health said "America's participation in a coordinated effort to help people around the world ensure access to the vaccine is invaluable. It will ultimately help end this devastating global health crisis."

  In a BMJ editorial, Schwartz said two doses of the vaccine were needed, adding that maintaining certain low temperatures posed a challenge to different countries.

  "Defining the operational challenges of the Global Covid-19 vaccine program quickly and effectively will be at least as difficult as the scientific challenges associated with the development of vaccines," he said.

  According to the authors of Johns Hopkins, the cost of this vaccine can range from $ 6 to $ 74 per course.

 Their observation is that even if each vaccine works properly, rich countries have allocated a single dose for each citizen.

  Researchers say Canada has ordered four doses of the same amount per person,

 

  The United States has a sufficient number of vaccine courses per person, while countries such as Indonesia have less than one vaccine course per two people.